PFOA and Kidney Cancer: The Science Behind the Hillhouse Question
Three of the world's most cited bodies on chemical carcinogenicity, the C8 Science Panel, IARC and the US EPA, have each examined PFOA and kidney cancer. This piece sets out exactly what each one found, in their own words, including the limits and caveats each body attached to its own finding.
From Lancashire’s Health Cell kidney-cancer report on the Hillhouse area.
This piece draws no conclusion about any specific location. It sets out, in each body’s own words, what has been found about PFOA and kidney cancer generally, the same chemical found in soil around the AGC Chemicals Europe (formerly ICI) plant at Hillhouse, Thornton-Cleveleys.
Three assessments, run independently over more than a decade, have each looked at PFOA (perfluorooctanoic acid) and kidney cancer: a court-ordered panel that studied 69,000 people, the world’s leading authority on classifying carcinogens, and the US government’s own toxicity review. Here is exactly what each one found, in its own words, including the limits each one placed on its own finding.
A court ordered a panel to study 69,000 people. It found a “probable link.”
The C8 Science Panel was a court-appointed body that studied roughly 69,000 people living near DuPont’s Washington Works plant in the Mid-Ohio Valley, an area with decades of high PFOA exposure through drinking water. In 2012 it concluded there was a “probable link” between PFOA exposure and six health outcomes, including kidney cancer and testicular cancer. “Probable link” was the Panel’s own term, meaning a connection is “more likely than not,” given all available evidence: a standard defined in the legal settlement that created the Panel, not a general statement of scientific proof.
One detail is worth stating plainly. The Panel’s own incidence study of the exposed population did not, on its own, show a statistically significant increase in kidney cancer (hazard ratio 1.10, a ratio where 1.0 would mean no extra risk at all; 95% confidence interval 0.98 to 1.24, a range that still includes “no extra risk”; trend p=0.18). “Probable link” was a weight-of-evidence synthesis across multiple studies, not a result from a single dataset. (For testicular cancer, the same study did show a significant trend.)
The world’s top classifier of carcinogens moved PFOA to its highest tier.
In 2023, IARC reclassified PFOA from Group 2B (“possibly carcinogenic”) to Group 1, “carcinogenic to humans,” its highest classification tier. The monograph (IARC’s detailed scientific report) named renal cell carcinoma (the main form of kidney cancer) and testicular cancer among the human tumour sites it considered.
Two things matter for reading this correctly. First, IARC itself rated the human epidemiological evidence for kidney cancer as “limited,” not “sufficient.” The Group 1 classification rests substantially on mechanistic evidence (how the chemical behaves in the body) and animal studies, not on human kidney-cancer data alone. Second, Group 1 is a hazard identification: a substance capable of causing cancer under some circumstances of exposure. It is not a dose, potency (how strong an effect is), or risk statement for any specific population or community.
The US EPA reached the same place in 2024, in plainer words.
In its 2024 final human health toxicity assessment, the EPA classified PFOA as “Likely to Be Carcinogenic to Humans.” Its own wording is direct: “the strongest evidence of an association between PFOA exposure and cancer in human populations is from studies of kidney cancer.”
Two more studies point the same way, with one important caveat.
Two studies are commonly cited alongside these classifications. Vieira et al. (2013), studying communities around the same Mid-Ohio Valley plant, found a kidney cancer odds ratio (again, a ratio where 1.0 means no difference) of about 2.0 (95% CI 1.3 to 3.1). Shearer et al. (2021), using blood samples taken before anyone was diagnosed from a study that followed a group of people forward over time, found a renal cell carcinoma odds ratio of 2.63 (95% CI 1.33 to 5.20), highest exposure quarter against lowest.
The Shearer study needs a specific caveat. Kidney function affects how PFOA is cleared from the body, raising the possibility of reverse causation: early, undiagnosed kidney impairment could itself raise measured PFOA levels, rather than PFOA causing the cancer. Shearer’s design, using blood taken before diagnosis in a group followed forward over time, is built to reduce this risk, but after adjusting for a marker of kidney function (eGFR), the estimate comparing exposure groups weakened and lost significance (odds ratio, OR, 2.19, 95% CI 0.86 to 5.61); only the estimate based on each doubling of PFOA level held (OR 1.68, 95% CI 1.07 to 2.63). Reverse causation is mitigated by some study designs in this literature, not eliminated by any of them.
What three independent bodies agree on, and what none of them claim.
Taken together, three independent bodies, using different methods and populations, recognise an association between PFOA exposure and kidney cancer. That is a documented, citable position of the current scientific and regulatory record.
It is not a finding about any specific site, community, or individual case. IARC’s classification is a hazard statement, not a dose-response finding (it does not say how much exposure produces how much added risk). The C8 Panel’s “probable link” is a weight-of-evidence judgment from a large, unusually well-studied group of people with high, sustained exposure, not a threshold that applies automatically elsewhere. None of the studies above prove that PFOA caused any particular person’s cancer, and none were conducted at, or designed to answer questions about, the Hillhouse site.
What they do provide is a precise vocabulary, “probable link,” “Group 1 hazard,” “likely to be carcinogenic”, against which any local assessment, including the one carried out by Lancashire County Council’s Health Cell, can be read.
How we know what we know
The C8 Science Panel’s finding is its own published “Probable Link Evaluation of Cancer” (2012), available at c8sciencepanel.org. IARC’s reclassification is Monograph Volume 135, “Perfluorooctanoic acid (PFOA) and perfluorooctanesulfonic acid (PFOS),” the 2023 evaluation. The EPA’s assessment is its “Final Human Health Toxicity Assessment for PFOA,” published May 2024. The two supporting studies are Vieira et al., “Perfluorooctanoic Acid Exposure and Cancer Outcomes in a Contaminated Community,” Environmental Health Perspectives (2013), and Shearer et al., “Serum Concentrations of Per- and Polyfluoroalkyl Substances and Risk of Renal Cell Carcinoma,” Journal of the National Cancer Institute (2021), read alongside Bartell & Vieira’s review applying modified Hill criteria (a standard checklist for judging whether a link is likely causal), Journal of the Air & Waste Management Association (2021). Every figure above is quoted or calculated directly from these sources.